GS
NUVB icon

GTS Securities’s Nuvation Bio NUVB Stock Holding History

GTS Securities’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,579
Closed -$15.5K – 4292
2023
Q3 		$15.5K Buy
+11,579
New +$19.3K ﹤0.01% 3809

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GTS Securities's NUVB Position: Q4 2023 in Review

GTS Securities sold out of Nuvation Bio (NUVB) in Q4 2023, closing a stake of 11,579 shares — an estimated $15.5K sold.

GTS Securities first reported a position in NUVB in Q3 2023 and held it in 1 quarter. The position peaked at $15.5K in Q3 2023. 116 funds tracked by Wall St. Rank hold NUVB as of Q4 2023.

  • GTS Securities reported no remaining Nuvation Bio position as of Q4 2023 after selling out during the quarter.
  • GTS Securities sold 11,579 Nuvation Bio shares in Q4 2023, an estimated $15.5K.
  • GTS Securities first reported a position in Nuvation Bio in Q3 2023 and held it in 1 quarter.
  • GTS Securities's Nuvation Bio position peaked at $15.5K in Q3 2023.
  • 116 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.